Ophthalmic emulsion composition
The microemulsion composition addresses the instability of existing ophthalmic formulations by combining sodium hyaluronate, omega fatty acids, and biopolymers, enhancing tear film stability and preventing corneal damage in dry eye disease.
Patent Information
- Application Number
- PCT/IB2026/054423
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing ophthalmic compositions fail to provide a stable combination of mucous, aqueous, and lipid components, leading to inadequate lubrication, inflammation, and potential corneal damage in dry eye disease.
A pharmaceutical microemulsion composition comprising sodium hyaluronate, omega fatty acids, and biopolymers like hydroxyethyl cellulose, along with a surfactant-cosurfactant system, to enhance hydration, lubrication, and prevent corneal deposits.
The composition improves tear film stability, reduces evaporation, and prevents corneal damage, providing effective relief for dry eye symptoms without phosphates or preservatives.
Smart Images

Figure IMGF000017_0001_TABLE 
Figure IMGF000018_0001_TABLE 
Figure IMGF000018_0002_TABLE
Abstract
Description
[0001] TITLE: OPHTHALMIC EMULSION COMPOSITION
[0002] Field of the Invention
[0003] The invention relates to an ophthalmic composition that can be used in the treatment of dry eye disease, providing 3 types of components that the natural tear contains: lipid component, aqueous component and mucoid component along with surfactant-cosurfactant system. The invention also relates to the method of preparation of the composition.
[0004] Background of the Invention
[0005] The eye is one of the most important and delicate organs in human body. The ocular surface, tear film, lacrimal glands, and eyelids act as a functional unit to preserve the quality of the refractive surface of the eye and to resist injury and protect the eye against changing bodily and environmental conditions. The tear film is the most dynamic structure of the functional unit, and is essential for maintaining the health of the ocular surface. The tear film is reported to be composed of three layers: the mucin or mucous layer, aqueous, and lipid layers. The mucin or mucous layer is the innermost and is the one in continuous contact with the cornea. The aqueous layer is the middle layer and is what is made mainly by the tear gland. The lipid layer is the outermost and is produced by the Meibomian glands. A dysfunction of any of these layers can result in dry eye disorder.
[0006] The dry eye disease is a common condition that occurs when the tears are not able to provide adequate lubrication. The tear instability led to inflammation and damage of the eye's surface. Some common symptoms of dry eye disorders include e.g., irritation, redness, burning, discharge, inflammation, eye fatigue, and blurred vision. In some severe cases, scarring of the cornea may occur. An option for the treatment of dry eye are artificial tears. In addition to that, the 3 fixedcomponents are aqueous and oily components, and they cannot be mixed in a regular solution.
[0007] US 8685945 B2 relates to ophthalmic formulations comprising a galactomannan, borate, and a cis-diol.
[0008] US 11730699 B2 discloses a lipid-based ophthalmic emulsion. It is directed to a lipid-based ophthalmic emulsion containing the gellable polymer hydroxypropyl guar and anionic lipids for improving desiccation protection and retention along with surfactant system containing two hydrophilic surfactants with HLB values ranging from 1 to 18.
[0009] US 7947295 B2 relates to pharmaceutical compositions for ophthalmic use. It is directed to use of combination of two polymers to control viscosity of the formulation.
[0010] US 10828320 B2 discloses artificial tear compositions and compositions for ophthalmic drug delivery comprising a galactomannan such as guar, hyaluronic acid, and a cis-diol.
[0011] There is a need to develop ophthalmic compositions containing all the three components i.e. mucous component, aqueous component, and lipid component with better stability and physicochemical parameters.
[0012] Summary of the Invention
[0013] The invention relates to an ophthalmic composition that can be used in the treatment of dry eye disease, providing the components that the natural tear contains: lipid component, aqueous component and mucoid component.
[0014] The objective of present invention is to provide an ophthalmic composition that helps ina) Improvement in the aqueous part through its hydration properties.
[0015] b) Improvement in the lipid layer that prevents aqueous evaporation and improves hyperosmolarity.
[0016] c) Improvement in the mucidic part.
[0017] d) Avoid possible corneal deposits with chronic use because it does not contain phosphates (free of phosphates).
[0018] e) Avoid damage or death of corneal epithelial cells with chronic use because it does not contain a preservative (preservative free).
[0019] This invention relates to a pharmaceutical microemulsion ophthalmic compositions comprising biopolymer, sodium hyaluronate and omega fatty acid and process of preparing the same.
[0020] In an embodiment, the present disclosure provides methods of treating or alleviating symptoms of a dry eye disorder, asthenopia, impaired vision, blurred vision, photophobia, astigmatism, and / or blepharitis. The methods involve identifying a subject having the dry eye disorder, asthenopia, impaired vision, blurred vision, photophobia, astigmatism, and / or blepharitis; and administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising arabinogalactan, hyaluronate and omega fatty acid alone and / or in combination with other ingredients.
[0021] The present inventors have discovered that the combination of polyethylene glycol- propylene glycol mixture and oleic acid demonstrates a synergistic effect relative to skin penetration and globule size when compared to compositions containing no polyethylene glycol- propylene glycol mixture.
[0022] Detailed Description of the Invention
[0023] The following description sets forth exemplary embodiments of the present technology. It should be recognized, however, that such description is notintended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
[0024] As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
[0025] The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and / or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."
[0026] The use of the term "or" in the claims is used to mean "and / or" unless explicitly indicated to refer only to alternatives or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and / or."
[0027] As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited, elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method and / or formulation of the invention.
[0028] Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term "about" includes the indicated amount ±10%. In other embodiments, the term "about" includes the indicated amount ±5%. In certainother embodiments, the term "about" includes the indicated amount ±1 %. Also, to the term "about X" includes description of "X".
[0029] The use of the term "for example" and its corresponding abbreviation "e.g." (whether italicized or not) means that the specific terms recited are representative examples and embodiments of the invention that are not intended to be limited to the specific examples referenced or cited unless explicitly stated otherwise.
[0030] The formulations of the present invention relate to the uses of the proposed components to meet the attributes of hydration, mucoadhesion, anti-inflammation and eye lubrication and protection.
[0031] a) Hydration component: High molecular weight Sodium hyaluronate (HA) has moisturizing action, retains water 100 times its own weight. This component also has anti-inflammatory effects and reduces the friction between the cornea and the eyelid.
[0032] b) Mucoadhesive component: Polymers such as cellulose derivatives (methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, and hydroxyethylcellulose), polyvinyl alcohol, polyacrylic acid, chitosan. Biopolymer, preferentially low viscosity Hydroxyethyl cellulose (HEC) is a multifunctional component.
[0033] c) Lipidic component: Omega fatty acid like polyunsaturated Omega-3 fatty acids, polyunsaturated Omega-6 fatty acids, and mono- and / or polyunsaturated Omega-9 fatty acids, preferentially Oleic acid. Oleic acid (Omega 9) acts as a lubricant and an emollient vehicle and as a corneal permeability enhancer.
[0034] d) Polyethylene glycols: These are aqueous bases that present better propagation capacity, pH, lubricity, stability and low irritability. They have protective and lubricating action and thus prevent the irritating effects of physical, chemical and mechanical agents, calming burning and itching. Polyethylene glycols can be selected from polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, etc.e) Propylene glycol: It has lubricating and protective action and thus prevents the effects of external irritating agents. Provides long-lasting protection as it is slowly removed.
[0035] The invention relates to a pharmaceutical microemulsion ophthalmic composition comprising lipophilic agents, hydrating agents, mucoadhesive agents, polyethylene glycol, and propylene glycol and process of preparing the same.
[0036] The invention further relates to a pharmaceutical microemulsion ophthalmic compositions comprising lipophilic agents, hydrating agents, mucoadhesive agents, polyethylene glycol, and propylene glycol optionally in combination with other inactive ingredients and process of preparing the same.
[0037] Although the present invention is described with respect to biopolymers; a hyaluronic acid or a salt thereof; and omega fatty acids, the invention is not limited thereto. The present invention can further comprise active ingredients selected from the group of corticosteroid, anti-inflammatory agent, beta-adrenergic receptor agonist, beta-blocker, prostaglandin, carbonic anhydrase inhibitor, alpha 2 adrenergic receptor agonist, antibiotic, antibacterial, antihistaminic / mast cell stabilizer alone or in combinations thereof.
[0038] Biopolymers
[0039] In the present invention, biopolymer is used to impart mucoadhesive property that would be adequate to achieve a longer contact time between the drop of the solution and the surface of the cornea, where the microvilli of the mucidic layer are found.
[0040] In accordance with the present invention, biopolymer that can be used are like but not limited to polymers such as hydroxyethyl cellulose (HEC),carboxymethylcellulose (CMC), hydroxypropylmethyl cellulose (HPMC), carboxyvinyl polymer, xanthan gum, any combinations thereof or the like.
[0041] In the preferred embodiment of the present invention biopolymer used is hydroxyethyl cellulose (HEC).
[0042] Hydroxy ethyl cellulose is a nonionic, water-soluble polymer primarily used as a mucoadhesive agent in ophthalmic formulations. The concentration of hydroxyethyl cellulose used in a formulation is dependent upon the solvent and the molecular weight of the grade.
[0043] In another embodiment the biopolymer used in the pharmaceutical ophthalmic compositions according to the present invention are in the range of about 0.01% to 5% w / v of composition; preferably 0.01, 0.5, 1, 2, 3, 4, or 5% w / v of composition or intermediate fraction thereof. In most preferred embodiment HEC is present in the concentration of 0.1 % w / v.
[0044] Hyaluronic acid or salt thereof
[0045] Hyaluronic acid or salt because of its chemical structure it has a high affinity for water.
[0046] In accordance with the pharmaceutical ophthalmic compositions of the present invention hyaluronic acid or salt thereof is used as a hydrating agent.
[0047] In an accordance of present invention hyaluronic acid can be used alone or in combination of salts thereof. In a preferred embodiment hyaluronic acid salt used is sodium hyaluronate.Hyaluronic acid or salts thereof have important water retention properties, with an affinity of 1000 times their own weight. This increases the wettability of the ocular surface and reduces friction of the cornea from blinking in dry eye.
[0048] The concentration of the hyaluronic acid or salt present in the pharmaceutical ophthalmic compositions according to the present invention is in the range of about 0.02% to 5% w / v of composition; preferably 0.01, 0.5, 0.75, 0.1, 0.2, 0.3, 0.4 or 0.5% w / v of composition or intermediate fraction thereof. In a preferred embodiment hyaluronic acid or its salt is present in the concentration of about 0.2% w / v. In the most preferred embodiment sodium hyaluronate is present in the concentration of about 0.2% w / v.
[0049] Oil Phase
[0050] In accordance with the present invention, the oil that forms part of the emulsion may be selected from vegetable oil, animal oil, mineral oil, fatty acids, medium chain triglyceride, fatty alcohols alone or any combinations of these oils and / or oily substances that are well tolerated in the eye. The preferred oils are medium chain triglycerides, vegetable oils, olive oil, sunflower seed oil, sesame seed soil, castor oil, mineral oil and glyceryl monostearate (GMS) or combinations thereof. The more preferred oils are castor oil, mineral oil and glyceryl monostearate (GMS) or combination thereof.
[0051] In accordance with the present invention, oil is present in concentration preferably between 0.1% and 1% w / v of composition.
[0052] In accordance with the present invention, oil phase consists of omega fatty acids.Omega Fatty acids
[0053] Omega fatty acids are used in ophthalmic compositions as a lipid lubricant or an emollient vehicle.
[0054] In accordance with the present invention, omega fatty acid is a fatty acid, a component of the oil or lipid type. Its fatty or oily properties can repair the deficiency of the lipid layer of dry eye, working like a lid of a pot that prevents the aqueous part of the tear from evaporating.
[0055] In accordance with the present invention the omega fatty acid used may be omega-3 fatty acid, omega-6 fatty acid or omega-9 fatty acid alone or in combinations thereof.
[0056] In accordance with the present invention the omega-3 fatty acids are selected from the group consisting of, but not limited to, a-linolenic acid (ALA), eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA).
[0057] In accordance with the present invention the omega-6 fatty acids are selected from the group consisting of, but not limited to linoleic acid (LA); gamma-linolenic acid (GLA) ; calendic acid; eicosadienoic acid; fihomo-gamma-linolenic acid (DGLA); arachidonic acid (AA, ARA); docosadienoic acid; adrenic acid; osbond acid; tetracos atetraenoic acid or tetracosapentaenoic acid.
[0058] In accordance with the present invention omega-9 fatty acids are selected from the group consisting of, but limited to hypogeic acid; oleic acid; elaidic acid; gondoic acid; mead acid; erucic acid; nervonic acid; or ximenic acid.
[0059] In the preferred embodiment of the present invention Omega-9 fatty acid is Oleic acid.Omega-9 fatty acid oleic acid can be used in eye drops to treat dry eye because it can act as a lipid lubricant and as an emollient vehicle.
[0060] The concentration of the omega fatty acid in the pharmaceutical ophthalmic compositions according to the present invention is in the range of about 0.02% to 5% w / v of composition; preferably 0.01, 0.5, 0.75, 0.1, 0.2, 0.3, 0.4 or 0.5% w / v of composition or intermediate fraction thereof. In preferred embodiment Omega fatty acid is present in the concentration of 0.1% w / v. In the most preferred embodiment the omega- 9 / oleic is present in the concentration of 0.1% w / v.
[0061] Cosurfactant
[0062] The cosurfactant may comprise any ophthalmically suitable molecule that can promote the flexibility of the interface to promote the formation of the microemulsion.
[0063] Preferably the co-surfactant is an ophthalmically suitable molecule that can penetrate into the interfacial film and produces a more fluid interface by allowing the hydrophobic tails of the surfactants to move freely at the interface.
[0064] The cosurfactant may comprise or consist of an alkanol, such as ethanol, propanol, or 1 -butanol; an alkane-diol, such as 1,2-Propane diol (Propylene Glycol) or 1,2-butane diol; an alkane-polyol, such as glycerol, glucitol, or polyethylene glycol, plurolisostearique (isosteric acid of polyglycerol), Plurololeique (Polyglycery-l,6-dioleate), Cremophor RH 40, or polyoxyethylene-10-oleyl ether (Brij 96V); PEG 200; and PEG 400; or combinations thereof.
[0065] Cosurfactants may also comprise distearoylphosphatidyl ethanolamine-N-poly(ethyleneglycol) 2000 (DSPE-PEG), poloxamer and a combination where one component is block copolymer of a glycol monomer and other is polymer conjugated phospholipid.Polyethylene glycol 400
[0066] Polyethylene glycol 400 is used in ophthalmic solutions for the relief of burning, irritation and / or discomfort that follows dryness of the eye. Polyethylene glycol 400 offers significant benefits due to its favorable biocompatibility. It is gentle on ocular tissues, exhibiting non-irritating characteristics, and is both non-ionic and inert, thereby avoiding any reactions with other formulation components. Moreover, it plays a crucial role in increasing the bioavailability of therapeutic agents that are poorly soluble in water.
[0067] In one embodiment, polyethylene glycol 400, may be present in quantities between about 0.1% and 2% w / v of the formulation.
[0068] In another embodiment, polyethylene glycol (PEG), may be present in an amount of between about 0.1 and about 1.0% w / v of the composition.
[0069] Propylene Glycol (PG)
[0070] Propylene glycol (PG) is a hygroscopic, amphiphilic cosurfactant with strong solubilizing and hydrating properties. It complements the action of primary surfactants by reducing interfacial tension and stabilising emulsions. Additionally, it acts as a humectant, helping to retain moisture on the ocular surface, which is especially beneficial in treating dry eye disease.
[0071] In one embodiment, propylene glycol (PG) may be provided in an amount of between about 0.1 and about 2.0% v / v of the composition.
[0072] In another embodiment, propylene glycol (PEG 400), may be present in an amount of between about 0.5 and about 1.0% w / v of the compositionCombination of polyethylene glycol and propylene glycol
[0073] It was found by the inventors of the present invention that the combination of polyethylene glycol-propylene glycol with oil phase offered synergistic effects relating to globules size of the microemulsion and skin penetration of the oil phase as well.
[0074] In this ophthalmic composition, the combined use of polyethylene glycol and propylene glycol ensures a stable, preservative-free emulsion that is safe, effective, and comfortable for prolonged use.
[0075] In one embodiment, polyethylene glycol is about 0.2% w / v and propylene glycol is about 0.2% w / v.
[0076] In one embodiment, polyethylene glycol is about 0.3% w / v and propylene glycol is about 0.5% w / v.
[0077] In one embodiment, polyethylene glycol is about 0.5% w / v and propylene glycol is about 0.75% w / v.
[0078] In one embodiment, polyethylene glycol is about 0.55% w / v and propylene glycol is about 1.0% w / v.
[0079] Surfactants
[0080] Surfactants are critical components in pharmaceutical formulations for stabilizing emulsions, enhancing solubility, and ensuring uniform dispersion of ingredients.
[0081] In accordance of present invention there are at least one surfactant used in the emulsion. The surfactants of present invention are selected from the group consisting of, but not limited to, sorbitan esters (such as Span or Arlacel), glycerolesters (such as glycerin monostearate), polyethylene glycol esters (such as polyethylene glycol stearate), block polymers (such as poloxamers (Pluronics®)), acrylic polymers (such as Pemulen®), ethoxylated fatty esters (such as polyoxyl 35 castor oil ,Cremophor® RH-40), ethoxylated alcohols (such as Brij®), ethoxylated fatty acids (such as polysorbate 80, Tween or Tween 20), monoglycerides, silicon based surfactants alone or in combinations thereof.
[0082] In a preferred embodiment, surfactants used is polysorbate 80.
[0083] Polysorbate 80
[0084] Polysorbate 80, a non-ionic surfactant, is widely used in ophthalmic preparations due to its excellent biocompatibility, emulsifying properties, and ability to reduce surface tension between immiscible phases.
[0085] Polysorbate 80, chemically known as polyoxyethylene (20) sorbitan monooleate, is a hydrophilic surfactant with an HLB (hydrophilic -lipophilic balance) value of approximately 15, making it highly suitable for oil-in-water emulsions. Its structure contains a hydrophilic polyoxyethylene chain and a lipophilic oleic acid moiety, enabling it to interact effectively with both aqueous and lipid phases.
[0086] In one embodiment of the present invention, surfactant is present at a concentration ranging from about 0.1% to 2% w / v.
[0087] In another embodiment, surfactant is present at a concentration ranging from about 0.5% to 2% w / v.
[0088] In accordance with the present invention, the composition may further comprise of one or more excipients selected from but not limited to isotonizing agents, stabilizers, buffers, preservatives, antioxidants.The composition of the present invention may include an isotonizing agent such as mannitol, glycerin, glycerol, sorbitol, glucose alone or combinations thereof.
[0089] In preferred embodiment the isotonizing agent is selected from glycerin, glycerol alone or combination thereof.
[0090] The composition of present invention may contain stabilizers such as sodium edatate, citric acid alone or combination thereof.
[0091] The composition of present invention may contain buffers such as tris(hydroxymethyl)aminomethane, sodium phosphate and potassium phosphate, sodium citrate, sodium carbonate, sodium bicarbonate, boric acid or pharmaceutically acceptable salts thereof alone or combinations thereof.
[0092] In one embodiment buffer of the present invention is selected from boric acid and sodium borate.
[0093] The composition of present invention may contain preservatives such as quaternary ammonium compound like benzalkonium chloride, chlorobutanol, sodium perborate alone or combinations thereof. In one of the embodiment of present invention, the preservative used is benzalkonium chloride.
[0094] In another preferential embodiment the composition of the present invention may be preservative free.
[0095] The compositions of the present invention may be sterilized by filtration or they may be obtained by sterilization of the aqueous phase and the oily phase and subsequently mixing and emulsifying in aseptic conditions.
[0096] Accordingly, an embodiment of the present invention discloses a pharmaceutical microemulsion ophthalmic compositions comprising:hydrating agent;
[0097] mucoadhesive agent;
[0098] lipophilic agent;
[0099] surfactant-cosurfactant system.
[0100] Accordingly, an embodiment discloses a pharmaceutical microemulsion ophthalmic compositions comprising;
[0101] a hydrating agent;
[0102] wherein the hydrating agent selected from the group of hyaluronic acid or a salts thereof;
[0103] mucoadhesive agents;
[0104] wherein the mucoadhesive agent is selected from biopolymers;
[0105] an oil phase dispersed in an aqueous phase;
[0106] wherein oil phase comprises of at least one omega fatty acid;
[0107] cosurfactant; and
[0108] surfactant.
[0109] Another embodiment discloses a pharmaceutical microemulsion ophthalmic compositions comprising;
[0110] a hyaluronic acid or a salt thereof;
[0111] biopolymers; wherein biopolymers are selected from carbomers like hydroxyethylcellulo se ;
[0112] an oil phase dispersed in an aqueous phase;
[0113] wherein oil phase comprises of at least one omega fatty acid;
[0114] wherein the oil phase includes oil globules having a mean globule size of less than 30 nm; and
[0115] a surfactant-cosurfactant system;
[0116] wherein the cosurfactant is selected from the group comprising of alkanol such as polyethylene glycol (PEG) 400, propylene glycol or in combination thereof.Another embodiment discloses a pharmaceutical microemulsion ophthalmic compositions comprising;
[0117] a hyaluronic acid or a salt thereof;
[0118] hydroxyethyl cellulose;
[0119] wherein about 0.1%-25% w / v of oil phase dispersed in an aqueous phase, wherein oil phase comprises of at least one omega fatty acid or combination thereof;
[0120] wherein the oil phase includes oil globules having a mean globule size of less than 30 nm;
[0121] polyethylene glycol (PEG) 400, propylene glycol or in combination thereof. a surfactant selected from the group comprising of polyoxyl 35 castor oil, polysorbate 80 alone or combination thereof;
[0122] Another embodiment discloses a pharmaceutical microemulsion ophthalmic compositions comprising;
[0123] a hyaluronic acid or a salt thereof;
[0124] hydroxyethyl cellulose;
[0125] wherein about 0.1%-25% w / v of oil phase dispersed in an aqueous phase; wherein oil phase comprises of at least one omega fatty acid or combination thereof;
[0126] wherein the oil phase includes oil globules having a mean globule size of less than 30 nm.
[0127] polyethylene glycol (PEG) 400, propylene glycol or in combination thereof; a surfactant;
[0128] wherein surfactant is selected from polyoxyl 35 castor oil, polysorbate 80.
[0129] Another embodiment discloses a pharmaceutical microemulsion ophthalmic compositions comprising;
[0130] a hyaluronic acid or a salt thereof;
[0131] hydroxyethyl cellulose;
[0132] oleic acid;polyethylene glycol (PEG) 400 and propylene glycol in combination; and polysorbate 80;
[0133] wherein the emulsion is characterized by having a negative zeta potential; wherein the emulsion has a viscosity of about lOcps to lOOcps.
[0134] Viscosity of the microemulsion was determined by Brookfield Rheometer DV3T. The rotation speed was 250 rpm and the viscosity was determined in centipoise from rheogram plotted using shear stress (dyn / cm2) and shear rate (1 / s).
[0135] In accordance of the present invention, the viscosity of the present invention is 20cps to 300cps. In preferred embodiment of the present invention viscosity of the present invention is 50cps to 200cps. In preferred embodiment of present invention, the viscosity of present invention is 80cps to 120cps.
[0136] EXAMPLES EXAMPLE 1:
[0137] A representative formulation for the composition according to the present invention is shown in Table no. 1.
[0138] TABLE NO. 1:
[0139] Components Percentage v / w
[0140] DI D2 D3 Sodium hyaluronate 0.2 0.2 0.2 Oleic acid 0.1 0.1 0.1 Hydroxy
[0141] 0.1 0.1 0.1 ethylcellulose
[0142] Polyethylene glycol
[0143] 0.1 0.1 0.55
[0144] 400
[0145] Propylene glycol 0.1 0.1 1.0
[0146]
[0147] Polysorbate 80 0.1 1.3 1.3 Boric acid 0.3 0.3 0.3 Sodium borate 0.05 0.05 0.05 Sodium chloride 0.2 0.2 0.2 Purified water q.s q.s q.s
[0148]
[0149] Example 2: Process of preparation
[0150] The microemulsion compositions shown in Table 1 were prepared by using following method:
[0151] 1. Aqueous phase preparation
[0152] 1.1. boric acid and sodium borate were dissolved in purified water.
[0153] 1.2. sodium chloride was added to the previously prepared solution of (1.1) 1.3. hydroxyethyl cellulose and sodium hyaluronate were dissolved in the solution of (1.2).
[0154] 2. Oil phase preparation
[0155] 2.1. polyethylene glycol, propylene glycol, polysorbate and oleic acid were mixed together.
[0156] 3. Microemulsion preparation
[0157] Aqueous phase and oil phase were mixed obtaining a transparent microemulsion.
[0158] Example 3: Appearance, Globule size, and Phase separation
[0159] Physical properties of the preparations DI, D2, and D3 were examined for Appearance, Globule size, and Phase separation. The results are given is Table no.
[0160] 2.
[0161] TABLE NO 2: Appearance, Globule size, and Phase separation
[0162] Initial Phase Separation Experiments Globule size (nm)
[0163] Appearance initial
[0164] DI Cloudy 2148.60 Insoluble top layer
[0165]
[0166] Particulate matter D2 Slightly cloudy 1695.06 sedimented to the bottom
[0167] No precipitation or D3 Translucent 41.94
[0168] separation
[0169]
[0170] EXAMPLE 4:
[0171] Preparing Ophthalmic microemulsions with different concentrations of sodium chloride.
[0172] Concentration (v / w)
[0173] Sodium
[0174] Bl B2 B3 chloride
[0175] 0.12 0.16 0.20
[0176]
[0177] The batches were prepared as per formula of Example 1 and the process of Example 2.
[0178] Brief Description of the Drawings
[0179] Fig. 1 shows the effect of the addition of salts in the Triple Tear formula on the viscosity of the product. It can be seen that the initial viscosity drops considerably when using a percentage of 0.12%, 0.16% and 0.20% of sodium chloride.
[0180] Example 5: A formulation (Cl) was prepared as per formula of Example 1 and the process of Example 2 but without polyethylene glycol and propylene glycol.
[0181] Example 6: To study the effect of polyethylene glycol / propylene glycol with oleic acid, two comparative formulations as per Table no. 3 were prepared using process of Example 2.TABLE NO.3
[0182] Components Percentage v / w
[0183] D3 Cl
[0184] Sodium hyaluronate 0.2 0.2
[0185] Oleic acid 0.1 0.1
[0186] Hydroxy
[0187] 0.1 0.1
[0188] ethylcellulose
[0189] Polyethylene glycol
[0190] 0.55 - 400
[0191] Propylene glycol 1.0 - Polysorbate 80 1.3 1.3
[0192] Boric acid 0.3 0.3
[0193] Sodium borate 0.05 0.05
[0194] Sodium chloride 0.2 0.2
[0195] Purified water q.s q.s
[0196]
[0197] The observations of effect of combination polyethylene glycol / propylene glycol with oleic acid on physicochemical properties of the formulation are shown in Table No. 4.
[0198] TABLE NO.4
[0199] Parameter D3 Cl
[0200] Appearance clear solution Cloudy solution Viscosity 110.7 cPs 82.31 cPs
[0201] Particle size 24.97 nm 1316.46 nm Osmolarity 280.0 mOsm / Kg 150.0 mOsm / Kg
[0202]
[0203] TABLE NO.5: Heat stress 8°C and 45°C / Thermal cycling 8°C-45°C Heat stress 8°C Heat stress 45 °C Cycling 8°C / 45°C DI Cloudy White supernatant with suspended particles Cloudy Slightly D2 Slightly cloudy White supernatant with suspended particles
[0204] cloudy D3 Transparent Transparent without precipitation Transparent
[0205]
[0206] The comparative data of the heat stress studies of DI, D2, and D3 are given in Table no. 5.
[0207] The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims
CLAIMS:
1. An ophthalmic composition comprising:a) a hydrating agent;b) a biopolymer;c) a lipophilic agent;d) a surfactant-cosurfactant system;wherein the preparation is free of preservatives.
2. The ophthalmic composition of claim 1, wherein hydrating agent is sodium hyaluronate.
3. The ophthalmic composition of claim 1, wherein biopolymer is selected from hydroxyethyl cellulose, methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, and, polyvinyl alcohol, polyacrylic acid, and chitosan.
4. The ophthalmic composition of claim 1, wherein the lipophilic agent comprises omega fatty acids or a combination thereof.
5. The ophthalmic composition of claim 1, wherein co-surfactant system is a combination of poly ethylene glycol 400 and propylene glycol.
6. The ophthalmic composition of claim 1, wherein surfactant is selected from ethoxylated fatty acids (such as polysorbate 80, Tween or Tween 20), sorbitan esters (such as Span or Arlacel), glycerol esters (such as glycerin monostearate), polyethylene glycol esters (such as polyethylene glycol stearate), block polymers (such as poloxamers (Pluronics®)), acrylic polymers (such as Pemulen®), ethoxylated fatty esters (such as polyoxyl 35 castor oil, Cremophor® RH-40), ethoxylated alcohols (such as Brij®), monoglycerides, and silicon based surfactants.
7. The ophthalmic composition of claim 1 or claim 2, wherein sodium hyaluronate is at a concentration of 0.02% to 5.0% w / v.
8. The ophthalmic composition of claim 1 or claim 3, wherein biopolymer is at a concentration of 0.01% to 5.0% w / v.
9. The ophthalmic composition of claim 1 or claim 4, wherein lipophilic agent is at a concentration of 0.02% - 5.0% w / v of oil phase dispersed in an aqueous phase.
10. The ophthalmic composition of claim 1, wherein the surfactant-cosurfactant system is at a concentration of 0.1% - 3.0% w / v.
11. The ophthalmic composition of claim 1 or claim 5, wherein the cosurfactant system comprises polyethylene glycol (PEG) 400 at a concentration of 0.1% to 2.0% w / v and propylene glycol at a concentration of 0.1% to 2.0% w / v.
12. The ophthalmic composition of claim 1 or claim 6, wherein the surfactant system is at a concentration of 0.5% to 2% w / v.
13. The ophthalmic composition of any one of claims 1 to 12, wherein the preparation is packaged in sterile, single-use containers to ensure preservative-free sterility.
14. The ophthalmic composition of any one of claims 1 to 13, wherein the preparation is formulated as an oil-in-water emulsion stabilized by the surfactant and cosurfactant system.
15. The ophthalmic composition of any one of claims 1 to 15, wherein the preparation is suitable for sensitive eyes, pediatric, or elderly patients.
